Acadia Pharmaceuticals Inc’s filing revealed that its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported $40133.0 on Apr 08 ’25. In the deal valued at $14.82 per share,2,708 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 59,456 shares worth roughly $0.85 million.
Then, Kihara James sold 1,028 shares, generating $15,235 in total proceeds. Upon selling the shares at $14.82, the PRINCIPAL ACCOUNTING OFFICER now owns 22,257 shares.
Before that, Kihara James sold 1,095 shares. Acadia Pharmaceuticals Inc shares valued at $18,670 were divested by the PRINCIPAL ACCOUNTING OFFICER at a price of $17.05 per share. As a result of the transaction, Kihara James now holds 21,275 shares, worth roughly $0.31 million.
Deutsche Bank initiated its Acadia Pharmaceuticals Inc [ACAD] rating to a Hold in a research note published on February 11, 2025; the price target was $22. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Morgan Stanley revised its rating on August 07, 2024. It rated ACAD as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of ACAD
On Tuesday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -0.21% to $14.35. Over the last five days, the stock has lost -3.43%. Acadia Pharmaceuticals Inc shares have fallen nearly -21.80% since the year began. Nevertheless, the stocks have fallen -15.93% over the past one year. While a 52-week high of $20.68 was reached on 02/21/25, a 52-week low of $13.40 was recorded on 04/09/25. SMA at 50 days reached $17.20, while 200 days put it at $16.84.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 14.02, which if violated will result in even more drops to 13.68. On the upside, there is a resistance level at 14.75. A further resistance level may holdings at 15.14. The Relative Strength Index (RSI) on the 14-day chart is 35.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.47%. Stochastics %K at 31.94% indicates the stock is a holding.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2025-03-31, growing by 1.22 million shares to a total of 15.62 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 14.4 million shares. There was a rise of 7.79%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 27, 2024 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
